Federal health officials have expanded access to updated COVID-19 booster shots for millions of children, extending Pfizer-BioNTech’s bivalent booster to ages 5 through 11 and Moderna’s updated booster to ages 6 through 17. The Food and Drug Administration’s October 12 authorization allows the vaccines to be given at least two months after completion of a primary series or a previous booster.

The decision broadens a vaccination strategy introduced at the end of August, when regulators authorized bivalent boosters for older adolescents and adults. The updated vaccines contain components directed at both the original SARS-CoV-2 strain and the Omicron BA.4/BA.5 lineages that dominate current U.S. circulation.

CDC follows FDA with a recommendation

Hours after the authorization, CDC Director Rochelle Walensky endorsed the expanded use following review of the available evidence. CDC’s recommendation makes the updated boosters available through the national vaccination program and encourages eligible children to receive them as the country enters fall and winter.

The policy effectively shifts booster strategy away from the original monovalent formulation for these age groups. Federal officials are betting that matching the vaccine more closely to circulating Omicron lineages can improve protection against infection and severe disease compared with repeatedly boosting only against the ancestral strain.

That approach began with the FDA’s August 31 bivalent authorization for Pfizer in people 12 and older and Moderna in adults 18 and older. The October action extends the same basic strategy down the pediatric age range.

Doses differ by product and age

Pfizer and BioNTech’s pediatric bivalent booster for ages 5 through 11 uses a 10-microgram dose. The companies’ authorization announcement says the updated dose includes messenger RNA encoding both the original virus spike protein and the Omicron BA.4/BA.5 spike protein.

Moderna’s authorization applies to children and adolescents 6 through 17, using age-appropriate doses of its bivalent product. The FDA relied in part on the extensive safety and immune-response record established by the companies’ original vaccines, together with data supporting the modified formulations.

The agency is using a regulatory model familiar from influenza vaccination, in which strain composition can be updated without requiring a completely new large efficacy trial every time the antigenic target changes. That approach reflects the practical need to respond to an evolving virus on a timetable measured in months rather than years.

Pediatric booster policy has changed quickly

The new recommendation comes less than five months after CDC first recommended an original-formulation booster for children ages 5 through 11. Its May guidance advised a booster at least five months after the primary Pfizer series for that age group, based on evidence that protection against infection waned over time.

Since then, BA.4 and BA.5 have replaced earlier Omicron lineages and regulators have sought to update booster composition before winter. The change illustrates the speed with which vaccine policy is adapting to viral evolution, accumulated population immunity and new epidemiologic data.

The American Academy of Family Physicians summarized the new pediatric authorizations and emphasized that clinicians will need to distinguish among primary-series products, age-specific doses and updated booster eligibility when advising families.

The objective is protection against severe disease through winter

The broadened booster campaign does not mean regulators expect vaccination to prevent every infection. Omicron lineages have shown substantial ability to infect people with prior vaccination or infection. The public-health goal is to strengthen immunity before winter, reduce severe outcomes and limit pressure on hospitals as COVID-19 circulates alongside influenza and other respiratory viruses.

Uptake may be the harder challenge. Many children have not completed a primary series, and booster coverage has generally lagged behind initial vaccination. Parents are also navigating repeated changes in recommendations, product names and intervals, increasing the importance of clear guidance from pediatricians and pharmacies.

The October 12 decision nevertheless marks a significant expansion of the updated-vaccine strategy. Children as young as 5 can now receive an Omicron-targeted booster, putting much of the school-age population on the same bivalent approach already recommended for adults. The next test will be whether families use the option in large enough numbers to materially strengthen population protection before winter respiratory-virus activity intensifies.